drugset / Trial / NCT02518789

Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

NCT02518789

Phase 4 Unknown 132 enrolled Tang-Du Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.

Timeline

Start
2015-09
Primary completion
2016-08
Completion
2016-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intravenous
Background Cisatracurium Small molecule 0.05 mg/kg Intravenous
Background Cisatracurium Small molecule 0.1 mg/kg Intravenous
Background Etomidate Small molecule 0.3 mg/kg Intravenous
Background Fentanyl Other / unclassified 5 g/kg Intravenous
Background Fentanyl Other / unclassified 8 g/kg Intravenous
Background Midazolam Small molecule 0.03 mg/kg Intravenous
Background Midazolam Small molecule 0.05 mg/kg Intravenous
Background Propofol Small molecule 4 mg/kg Intravenous
Background Propofol Small molecule 6 mg/kg Intravenous
Background Remifentanil Small molecule 0.1 ug/kg Intravenous
Background Remifentanil Small molecule 0.3 ug/kg Intravenous
Background Rocuronium Other / unclassified 0.6 mg/kg Intravenous

Indications

No indication recorded.